ReviewClinical pharmacokinetics1994
Pharmacokinetics of anti-infective agents in paediatric patients.
Review in Clinical pharmacokinetics, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 39 citations in OpenAlex.
- Pharmacokinetics of teicoplanin in an ICU population of children and infants.Pharmaceutical research · 2004Trial
- Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis.Antimicrobial agents and chemotherapy · 2004Trial
- Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.Antimicrobial agents and chemotherapy · 2001Trial
- A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B.Antimicrobial agents and chemotherapy · 2000Trial
- Influence of maturation and growth on cefetamet pivoxil pharmacokinetics: rational dosing for infants.Antimicrobial agents and chemotherapy · 1996Trial
- Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, in adult patients with advanced melanoma and neurofibromatosis type 1 (NF1) and model informed dosing recommendations for NF1 pediatrics.Frontiers in pharmacology · 2023Article
- Advances in Drug Discovery and Development for Pediatric Tuberculosis.Mini reviews in medicinal chemistry · 2016Review
- Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults.Pharmaceutics · 2011Article
- Gentamicin dosing for pediatric patients with congenital heart disease.Pediatric cardiology · 2010Article
- The Food and Drug Administration's deliberations on antidepressant use in pediatric patients.Pediatrics · 2005Article
- Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.Paediatric drugs · 2001Review
- Antibiotics in neonatal infections: a review.Drugs · 1999Review
- Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients.Drug safety · 1999Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various differences in drug disposition exist between children and adults. For example, the volume of distribution (Vd) for many drugs is larger in children than in adults. Other parameters, including excretion and elimination may be altered in children compared with adults. The penicillins and cephalosporins are used commonly for the treatment of infection in paediatric patients. The increased Vd in children contributes to the increased elimination half-life of these agents. Clearance of the acylureido-penicillins is increased in children with cystic fibrosis, a disease that decreases the elimination half-life for these drugs. Aminoglycosides distribute into extracellular fluid and their pharmacokinetic profile is affected by changes in Vd. The Vd for aminoglycosides is slightly higher in children than in adults. Children with cystic fibrosis, burns, or cancer have higher clearance rates and larger Vd values for aminoglycosides. Few data in the literature address the pharmacokinetics of other anti-infective agents, including vancomycin, teicoplanin, erythromycin, metronidazole, chloramphenicol, and cotrimoxazole (trimethoprim-sulfamethoxazole), in children. Similarly, there is little information regarding the pharmacokinetic profile of antivirals and antifungals in children. Dosage guidelines are available to enable the clinician to initiate anti-infective therapy in children. Subsequent dosage requirements may change based on the patient's current clinical condition. Although several studies have investigated the pharmacokinetics of anti-infectives in neonates and adults, data for children are limited. Therefore, further studies are required so that the ever growing arsenal of anti-infectives can be administered appropriately to children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.